Mesentech

Mesentech has developed a bone-targeting prodrug MES1007 that avoids systemic exposure and side effects by specifically delivering drugs to the bone. Over the years, Mesentech founders have developed unique partnership with Merck, Cure Duchenne, and Charles H. Hood Foundation.